Worldwide orthopaedic product sales reached $46.6 billion in 2015, an increase of 1.2 percent over 2014, according to ORTHOWORLD® estimates. The numbers cited in the latest installment of THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT® show that industry growth slowed from the two to three percent range in recent years due to various economic and industry factors.
Coatings and surface treatments that encourage bony ingrowth are as popular now as ever. The technologies that allow for such growth, however, are changing. As 3D-printed implants and nanotechnology allow for new forms of coatings, companies are starting to experiment with these technologies.
A partnership between manufacturers and suppliers should be an acutely sought-after deliverable to assure success as global sourcing continues to flourish. Companies that face the risks head on will then co-share the profits when an effective Quality Agreement becomes a foundation point.
Bundled payments and burden of evidence have changed the way that products are developed and launched. One theme surfaces as a necessary reminder: the sooner a company includes reimbursement in their commercialization preparations, the better-armed they are for market entry and the more immediate the revenue stream.
BONEZONE spoke with four device companies, ranging from early-stage to large player, that are responding to surgeon and patient trends in a number of ways. Some are launching and refining diverse product portfolios to cover a range of procedures, while others are focusing on specific clinical needs.
